Stallergenes Greer : 2018 sales in line – 2018 EBITDA at the lower end of the range of forecasts – Neutral vs Buy - target price € 32.5 vs € 37
>H2: market share regained for Staloral… - The full-year sales totalled € 277m (+6% and +8% l-f-l), i.e. € 136.5m of which southern Europe (+15%), northern and central Europe, € 33.5m (+0%), US € 91.3m (+4%), and RoW, € 15.7m (-20%). By product category, the sales breakdown is as follows: sublingual € 172.9m, i.e. +10%, subcutaneous: € 70.1m (+0%), veterinary products: € 9.4m (-8%) vs € 9m estimated and other products: € 24.6m (+7%) vs € 25m estimated.This ...Stallergenes Greer is engaged in providing a comprehensive approach to allergies diseases, offering allergy specialists a range of products from diagnosis to sublingual and subcutaneous allergen immunothreaphy medicines. Co. portfolio comprises of four product categories; Sublingual products include ORALAIR® and STALORAL®; Subcutaneous products include ALUSTAL®, PHOSTAL®, ALYOSTAL ® and ALBEY®, and GREER EXTRACTS®; Veteninary product is a range of USDA-approved bulk extracts for animals suffering from a range of allergies; and Other products offer a variety of diagnostic tools and source materials in useful formulations for allergy specialists and physicians.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.